SRx Health Solutions (SRXH) Q2 2026 earnings summary

Executive summary

• Transitioned to a single Consumer Products segment focused on premium pet food after discontinuing Canadian healthcare operations and restructuring under CCAA.

• Achieved a sequential 23% increase in net revenue to $3.4 million for Q2 FY26, marking an operational inflection point.

• Adjusted EBITDA loss improved 44% quarter over quarter to $(0.6) million, and net loss improved 26% to $(6.4) million.

• Strengthened liquidity with $20.5 million in cash at quarter end, up from $1.3 million at September 30, 2025.

• Strategic investments in digital assets and equity securities, and a pending $55 million EMJX acquisition.

Financial highlights

• Net sales/revenue grew 23% quarter over quarter to $3.4 million for the quarter ended March 31, 2026.

• Gross profit: $1.3 million, gross margin 37%.

• Net loss from continuing operations: $6.4 million; discontinued operations: $10.1 million loss.

• Adjusted EBITDA for the quarter was $(0.6) million, a 44% improvement quarter over quarter.

• Cash and cash equivalents at quarter-end: $20.5 million; short-term investments: $3.0 million.

Outlook and guidance

• Focus on stabilizing operations, optimizing cost structure, and pursuing targeted growth in pet health products.

• Strategic initiatives include AI-enabled analytics, digital treasury management, and opportunistic investments in digital assets.

• Management expects sufficient liquidity for the next twelve months and is evaluating strategic alternatives.

• Anticipates closing the EMJX acquisition prior to the end of Q3 FY26.